Aptevo Therapeutics Inc (APVO)

$6.76 -0.78 (-10.34%)
Market Cap 7.25M
Revenue (ttm) 0.00
Net Income (ttm) -24.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 102,300
Avg Vol 216,216
Day's Range N/A - N/A
Shares Out 998,000.00
Stochastic %K 8%
Beta 1.47
Analysts Sell
Price Target $377.70

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 838 0500
Fax: 206 838 0503
Address:
2401 4th Avenue, Suite 1050, Seattle, United States
Traildog19
Traildog19 Feb. 4 at 2:30 AM
$APVO the $60ML ELOC facility can fund them into 2029 so clinical and preclinical milestones are achieved. Great remission data so far. So why is it tanking?
0 · Reply
MicrocapCowboy
MicrocapCowboy Feb. 3 at 6:41 PM
$APVO no, it's not a lie or scam.....the pipeline is real and you just don't understand how clinical research companies start-up if you think it is. However, a lot of retail investors are thinking the fat lady is singing because the CEO just got bounced. But back to the facts, the pipeline is not fabricated...it's real and has incredible intrinsic value. Say what you're going to say...sell your 200 shares or whatever and whine, but I'm sticking around and expect to see explosive appreciation very soon.
0 · Reply
Rasa1427
Rasa1427 Feb. 3 at 4:05 PM
$APVO
0 · Reply
MicrocapCowboy
MicrocapCowboy Feb. 3 at 3:23 PM
$APVO If you know a little about corporate leadership history, you know companies do not become powerhouses because of their founders....it's typically the guy that comes in next that does it. GE is a great example. If Thomas Edison or JP Morgan had continued to run the company, it wouldn't have made it into the 20th Century. Edison had ideas and Morgan had money, but neither could run it. They turned it over to a guy named Charles Coffin who was part of their group but not in charge. They made him their first president and the rest is history. Is Lamothe another Charles Coffin?
0 · Reply
MicrocapCowboy
MicrocapCowboy Feb. 3 at 3:12 PM
$APVO Now, if we can just get the government opened back up....the last shutdown is the main reason we are still here sitting on our hands.....slowed the advancement by at least a quarter, maybe more.....APVO 436 should have been full phase III before Thanksgiving.
0 · Reply
MicrocapCowboy
MicrocapCowboy Feb. 3 at 3:07 PM
$APVO This news is much anticipated. Strategically, that change needed to happen ahead of the next major pipeline advancement. So this tells me, it is upon us. It's forcing out some week hands at the moment, but so what....just hold and wait.
0 · Reply
DARKP00L
DARKP00L Feb. 3 at 1:14 PM
$APVO 08:14 on Feb. 03 2026 Aptevo Therapeutics President, CEO Marvin White To Retire, Effective April 1, Transitioning To Executive Chair; COO Jeff Lamothe Appointed President, CEO #tradeideas
1 · Reply
AZOZ
AZOZ Feb. 3 at 12:48 PM
$APVO Oversold swing idea 💡
0 · Reply
brj1323
brj1323 Feb. 2 at 5:25 PM
$APVO ripe for a pump, got the avg down to $8.15
0 · Reply
IAmMsMoneyMaker
IAmMsMoneyMaker Feb. 2 at 4:26 PM
$PHGE Ready to EXPLODE to the UPSIDE!🥳 Also… JUST A MATTER OF TIME… ⏳ ⌛️ $APVO $FUSE $ECDA
0 · Reply
Latest News on APVO
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Feb 3, 2026, 8:05 AM EST - 18 hours ago

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Jan 9, 2026, 8:05 AM EST - 25 days ago

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

Dec 26, 2025, 8:05 AM EST - 5 weeks ago

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

Dec 9, 2025, 8:05 AM EST - 2 months ago

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Nov 10, 2025, 8:05 AM EST - 3 months ago

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Nov 6, 2025, 8:05 AM EST - 3 months ago

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Oct 8, 2025, 8:20 AM EDT - 4 months ago

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Sep 16, 2025, 8:30 AM EDT - 5 months ago

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Sep 4, 2025, 8:45 AM EDT - 5 months ago

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 13, 2025, 8:05 AM EDT - 6 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aug 11, 2025, 8:05 AM EDT - 6 months ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 11:30 AM EDT - 8 months ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:55 AM EDT - 8 months ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 20, 2025, 8:01 AM EDT - 8 months ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 1:34 PM EDT - 8 months ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 11:37 AM EDT - 8 months ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 10:52 AM EDT - 8 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 18, 2025, 8:01 AM EDT - 8 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Aptevo Participating in the BIO International Convention

Jun 13, 2025, 8:05 AM EDT - 8 months ago

Aptevo Participating in the BIO International Convention

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 22, 2025, 8:05 AM EDT - 9 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 15, 2025, 8:05 AM EDT - 9 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

May 8, 2025, 8:45 AM EDT - 9 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 22, 2025, 4:05 PM EDT - 10 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 10 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 10 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 10 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 20, 2025, 8:35 AM EDT - 11 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 18, 2025, 8:05 AM EDT - 11 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Aptevo to Participate in March Conferences

Mar 6, 2025, 8:00 AM EST - 11 months ago

Aptevo to Participate in March Conferences

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 15, 2025, 6:59 PM EST - 1 year ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Feb 14, 2025, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Jan 15, 2025, 8:00 AM EST - 1 year ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 12:50 PM EST - 1 year ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 12, 2024, 9:00 AM EST - 1 year ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Dec 4, 2024, 8:35 AM EST - 1 year ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 29, 2024, 9:55 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 26, 2024, 8:35 AM EST - 1 year ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 22, 2024, 8:35 AM EST - 1 year ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 20, 2024, 8:35 AM EST - 1 year ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 11, 2024, 8:15 AM EST - 1 year ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Nov 7, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

May 14, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

May 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Traildog19
Traildog19 Feb. 4 at 2:30 AM
$APVO the $60ML ELOC facility can fund them into 2029 so clinical and preclinical milestones are achieved. Great remission data so far. So why is it tanking?
0 · Reply
MicrocapCowboy
MicrocapCowboy Feb. 3 at 6:41 PM
$APVO no, it's not a lie or scam.....the pipeline is real and you just don't understand how clinical research companies start-up if you think it is. However, a lot of retail investors are thinking the fat lady is singing because the CEO just got bounced. But back to the facts, the pipeline is not fabricated...it's real and has incredible intrinsic value. Say what you're going to say...sell your 200 shares or whatever and whine, but I'm sticking around and expect to see explosive appreciation very soon.
0 · Reply
Rasa1427
Rasa1427 Feb. 3 at 4:05 PM
$APVO
0 · Reply
MicrocapCowboy
MicrocapCowboy Feb. 3 at 3:23 PM
$APVO If you know a little about corporate leadership history, you know companies do not become powerhouses because of their founders....it's typically the guy that comes in next that does it. GE is a great example. If Thomas Edison or JP Morgan had continued to run the company, it wouldn't have made it into the 20th Century. Edison had ideas and Morgan had money, but neither could run it. They turned it over to a guy named Charles Coffin who was part of their group but not in charge. They made him their first president and the rest is history. Is Lamothe another Charles Coffin?
0 · Reply
MicrocapCowboy
MicrocapCowboy Feb. 3 at 3:12 PM
$APVO Now, if we can just get the government opened back up....the last shutdown is the main reason we are still here sitting on our hands.....slowed the advancement by at least a quarter, maybe more.....APVO 436 should have been full phase III before Thanksgiving.
0 · Reply
MicrocapCowboy
MicrocapCowboy Feb. 3 at 3:07 PM
$APVO This news is much anticipated. Strategically, that change needed to happen ahead of the next major pipeline advancement. So this tells me, it is upon us. It's forcing out some week hands at the moment, but so what....just hold and wait.
0 · Reply
DARKP00L
DARKP00L Feb. 3 at 1:14 PM
$APVO 08:14 on Feb. 03 2026 Aptevo Therapeutics President, CEO Marvin White To Retire, Effective April 1, Transitioning To Executive Chair; COO Jeff Lamothe Appointed President, CEO #tradeideas
1 · Reply
AZOZ
AZOZ Feb. 3 at 12:48 PM
$APVO Oversold swing idea 💡
0 · Reply
brj1323
brj1323 Feb. 2 at 5:25 PM
$APVO ripe for a pump, got the avg down to $8.15
0 · Reply
IAmMsMoneyMaker
IAmMsMoneyMaker Feb. 2 at 4:26 PM
$PHGE Ready to EXPLODE to the UPSIDE!🥳 Also… JUST A MATTER OF TIME… ⏳ ⌛️ $APVO $FUSE $ECDA
0 · Reply
Quagglerock
Quagglerock Feb. 1 at 10:19 PM
$APVO I'm genuinely confused over the past 3 weeks of activity here. On January 9th, Aptevo PR'd that they were entered into a $60 million equity line of credit with Yorkville. They PR said that this LOC together with cash on hand was enough to get them through 2029 and that they did this to be conservative and limit further dilution. Within several weeks, they turn around a stockholder proposal to issue more than 19.99% of outstanding shares for additional sale. I don't understand what I'm missing between these two events. They appear to be in stark contrast with one another.
0 · Reply
BLOCKS77
BLOCKS77 Feb. 1 at 12:21 AM
$APVO Voted NO! NO! YES!
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Jan. 31 at 11:55 PM
$APVO dear apvo board of directors, this is the attitude I'm bringing to respond to the invite to the shareholders meeting where you expect us to approve Dilution by any amount you want over 20%:
0 · Reply
Southshd
Southshd Jan. 30 at 3:58 PM
$APVO
0 · Reply
Southshd
Southshd Jan. 30 at 3:40 PM
$APVO Market Cap goes up by 60% from 7 mil to 11mil and the stock goes down. Think about that as a current share holder! Stock is suppose to go up 60% and follow the MC! This has been the continued fleecing of current share holders! This has to end with a class action law suit!
2 · Reply
Felixii
Felixii Jan. 30 at 3:17 PM
$APVO this is the biggest scam
0 · Reply
Southshd
Southshd Jan. 30 at 3:14 PM
$APVO Do a reverse stock split so you can just add more shares! How can one company have this little interest in share holders and still be employed? vote no in February! Sell the company or closed doors while we supposedly have $20 per share in cash! Stop fleecing share holdets!
0 · Reply
Southshd
Southshd Jan. 30 at 3:09 PM
$APVO Does anyone know how they increase shares by over 50% today. Yesterday under 1 mil shares now 1.5 mil shares? Wow
0 · Reply
Felixii
Felixii Jan. 29 at 4:51 PM
$APVO this stock 🙈
0 · Reply
Southshd
Southshd Jan. 29 at 3:45 PM
$APVO This needs some serious insider buyers at these numbers if they have any conviction in this company?!
0 · Reply
David_M_
David_M_ Jan. 28 at 10:55 PM
$APVO New 52-week low
0 · Reply
David_M_
David_M_ Jan. 28 at 4:06 PM
$APVO
0 · Reply